CN1083265C - 改进的含有布洛芬和可待因的药物配方 - Google Patents
改进的含有布洛芬和可待因的药物配方 Download PDFInfo
- Publication number
- CN1083265C CN1083265C CN95195426A CN95195426A CN1083265C CN 1083265 C CN1083265 C CN 1083265C CN 95195426 A CN95195426 A CN 95195426A CN 95195426 A CN95195426 A CN 95195426A CN 1083265 C CN1083265 C CN 1083265C
- Authority
- CN
- China
- Prior art keywords
- prescription
- codeine
- ibuprofen
- mixture
- vegetable oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 title claims abstract description 74
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 38
- 229960004126 codeine Drugs 0.000 title claims abstract description 37
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims abstract description 18
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000314 lubricant Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 12
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000008117 stearic acid Substances 0.000 claims abstract description 12
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- -1 stearate ions Chemical class 0.000 claims abstract description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940080313 sodium starch Drugs 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- KVCWSJZUKMSPLM-UHFFFAOYSA-N O.O[PH2]=O Chemical compound O.O[PH2]=O KVCWSJZUKMSPLM-UHFFFAOYSA-N 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229940032147 starch Drugs 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N clofedanol Chemical compound C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 WRCHFMBCVFFYEQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000850 decongestant Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 241001440269 Cutina Species 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008173 hydrogenated soybean oil Substances 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 101000894524 Bos taurus Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 claims 1
- 101000798717 Homo sapiens Transmembrane 9 superfamily member 1 Proteins 0.000 claims 1
- 102100032463 Transmembrane 9 superfamily member 1 Human genes 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000007891 compressed tablet Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 31
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940040145 liniment Drugs 0.000 description 7
- 239000000865 liniment Substances 0.000 description 7
- 229910002012 Aerosil® Inorganic materials 0.000 description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 5
- 239000007894 caplet Substances 0.000 description 4
- 239000007941 film coated tablet Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000014593 oils and fats Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 101150085697 PVIP gene Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229940082170 ibuprofen 200 mg Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及布洛芬和可待因(或其任一的药学可接受的盐)的配方,其中包括一种载体,该载体包含崩解剂、稀释剂和润滑剂,此润滑剂基本上不含硬脂酸和硬脂酸盐离子,并选自氢化植物油。优选地配方是有效治疗疼痛及炎症的直接压缩片剂。
Description
本发明涉及改进的含有布洛芬和可待因(作为活性成分)的药物配方、制备这些配方的方法及其在治疗中的用途。
布洛芬,其化学名称为2-(4-异丁基-苯基)丙酸,是一种已知的非甾族抗炎药物(或NSAID)。它具有抗炎、退热和镇痛作用,并以该酸本身的形式或其适用于药物的盐的形式,例如钠盐,应用于治疗和预防疼痛和炎症,如类风湿性关节炎、头痛、神经痛、痛经、减少血小板粘连,牙痛及类似病情。
可待因,其化学名称为7,8二脱氢-4,5-环氧-3-甲氧基-17-甲基-吗啡喃-6-醇,是已知的一种麻醉止痛剂,通常以其适用于药物的盐的形式,如乙酸盐、氢溴化物、氢氯化物、水杨酸盐、硫酸盐或优选磷酸盐,通常以水合或部分水合的形式,如半水合形式,用在治疗或预防疼痛,尤其是严重的疼痛上。
布洛芬和可待因的组合被建议作为一种具有特效的麻醉剂。例如Cooper等人,在(1980)249,27(2),临床药物和治疗中报道了将化合物用于牙阻生手术后有中等到严重疼痛的患者身上后,具有好的效果。欧洲专利说明书388125公开了该组合在治疗急性疼痛如头痛及牙痛上的用途。
欧洲专利说明书535841公开了该组合用于治疗慢性疾病的疼痛,如骨关节炎、类风湿性关节炎、类风湿性脊椎炎、浆膜关节病、滑囊炎、肩周炎、腱炎、腱鞘炎和癌症。
但在一段时期大家公认,含有布洛芬和可待因的组合的配方的贮藏性能是不能令人满意的,如常用的剂型给药方式即片剂给药方式中尤其如此。经过一段时间和温度升高后,可发现传统的布洛芬加可待因配方退色,并开始因裂化和膨胀而分解。因此,要提出的问题是如何生产出“白色”片剂(如其中的组分是有很好的颜色稳定性,并不因时间或温度而退色或变黄)并同时不因储存而分解。为配方的目的,这些组分也应具有良好的可直接压缩性。
同样问题虽然在欧洲专利说明书159852中也提出了,但它是从在制备片剂的湿成粒处理过程中避免活性组分的紧密物理接触这一观点出发的。提出的解决方法是使用另一种改进的处理过程,即:将其中一种活性组分与粘合剂和填料掺合;将这些制出的混合物在有溶剂的情况下湿法成粒;干燥已成粒的混合物;过筛成粒的混合物;并将此混合物与一种或多种其它药理学活性组分掺合。但这样一种多步骤处理过程的缺点是不言而喻的。
欧洲专利说明书220805公开了解决此问题的一种改进方法,尤其是在与布洛芬加可待因片剂相关的低抗碎强度和长的崩解倍数的难题上。其中提出的解决方案是制得一种多相片剂:其中,例如可待因,可与如布洛芬、硬脂酸和硬脂酸盐脱离,并且,例如布洛芬可一样与可待因、硬脂酸和硬脂酸盐脱离。并且进一步,其中可待因相和布洛芬相至少包含一种自身润滑的压缩辅助剂(如微晶纤维素或者一种不流动、直接可压缩淀粉)。但是,即便这样此改进方法因其多相组分而显示出自身的问题。前面提及的欧洲专利说明书535841号公开了双层片剂。
可是,布洛芬加可待因的单相配方的公开,指出为提供一种满意的配方,硬脂酸和/或硬脂酸盐是必需的。例如欧洲专利说明书68838尽管只公开了氟比洛芬与包含硬脂酸镁的麻醉止痛剂,但并不特指布洛芬/可待因。前述的欧洲专利说明书388125只公开了在配方中含有硬脂酸的布洛芬加可待因片剂。欧洲专利说明书274845也提出了同样的问题,其公开的解决方法是在包括布洛芬加可待因的固体组分中给合羧基甲基片纤维素的不溶性盐。但是,即使用这种方法也指出要包含硬脂酸或硬脂酸镁作为润滑剂,尤其是硬脂酸。
那么,似乎采用一种多相配方是避免在配方中使用硬脂酸/硬脂酸盐的唯一方法,但相信这会引起或加重储存问题。但我们惊奇地发现一种配方,可以不使用硬脂酸或硬脂酸盐制备,并且这一配方是单相的,具有直接压缩性,并且通过采用氢化植物油作润滑剂的方法,克服了现有技术与布洛芬加可待因组合相关的稳定性和贮存问题。
因此,本发明提供了一种含布洛芬和可待因(或一种它们各自的适用于药物的盐)与一种适用于药物的载体所组合的药物配方,其中所述载体包含润滑剂、分解剂、及稀释剂,其特征在于,所述润滑剂基本上不合硬脂酸和硬脂酸盐离子,并且是从氢化植物油中挑选的。
优选地,润滑剂中,和,更优选地,整个配方中也基本上不含金属离子,如镁或其它微量杂质如铝及铁离子。“基本不含”在本文中是指所述金属离子可存在于ppm级的范围内(但优选少于10ppm),但优选不在百分之几或百分比的范围。
一种优选的氢化植物油选自氢化豆油和氢化蓖麻油及其混合物如甘油脂。油脂优选的例子是C16-C20甘油脂和三(12-羟基)硬脂酸甘油酯。一种这样的优选油脂是英国Hull Hul OQA的Karlshamns出售的以“sterotex K”命名的,同样适用的还有Castorwax,Castorwax M70,Castotrax MP80、Genwachs G、Cerit CH,Opalwax,Ceroxin及Cutina。
尤其令人惊奇的是,根据本发明的配方,崩解剂例如交联的聚乙烯基吡咯烷酮(PVP),交联羧甲基纤维素纳和淀粉甘醇酸钠可以在该配方中满意地使用。尤其是,交联羧甲基纤维素钠和特别是淀粉甘醇酸钠或它们的混合物用在该配方中是优选的崩解剂。令我们惊奇的部分原因是前述欧洲专利说明书274845指出“包含列出的有效水平的崩解剂”的配方“储存在50℃,定期观测其退色和膨胀或分解情况。只有含羧甲基纤维素的组分给出满意的结果,并且所有其它配方在12周内或多或少退色、膨胀或崩解,因而未能显示满意的储存性能。”相反,我们发现,当将氢化植物油作为滑润剂时,在使用所列出的崩解剂的情况下,在片剂一定时间和温度下(例如40℃时储存三个月),在保持“白色”及稳定性方面获得了满意效果。
本发明进一步提供了一种前面已经详细说明了的配方,其中优选崩解剂是交联羧甲基纤维素钠;淀粉甘醇酸盐,如淀粉甘醇酸钠(可以由Tunnel Avebe淀粉公司获得);以及聚乙烯基吡咯烷酮(PVP),如交联的PVIP;以及它们的混合物。更优选地,淀粉甘醇酸钠和/或在每660mg配方中至多达到20mg的交联羧甲基纤维素钠作为崩解剂。
优选地,本配方进一步包含可随时压缩的润滑剂,例如一种从乳糖和纤维素或它们的混合物中挑选的润滑剂;优选为β-单水乳糖和/或纤维素;更优选为72-76%的单水乳糖加23%-27%的纤维素(基本比例3∶1);以乳糖和纤维素的重量计算,可任选含有3-5%的,如可从德国Meggle公司得到的Cellactose(注册商标),如Cellactose 80;可任选为微晶纤维素,如微晶纤维素PH102(可以由F.M.C获得的Avicel)和/或羧甲基纤维素。Cellactose是特别优选的润滑剂。
本领域常规用的其它成分也可加入配方(但不是硬脂酸或硬脂酸盐),如流动增强剂或加强润滑剂,例如硅胶,如可以由德国Wacker-ChemieGmbH/Degussa购得的胶体二氧化硅,优选每200mg布洛芬至多含大约3mg。其它成分包括(但不限于此)粘合剂和压缩辅助剂,如发酵的玉米淀粉、羟基丙基纤维素(可以由Shinetsu/Dow购得)、微晶纤维素、聚乙烯吡咯烷酮、凝胶和树胶;润滑剂或填充剂如乳糖、氯化钠、山梨醇、甘露醇、微晶纤维素、磷酸钙和硫酸钙;另外的滑润剂如聚乙二醇类(如,PEG400及PEG6000)(但不包括前面提到的硬脂酸或其盐);表面活性剂或加湿剂,如十二烷基硫酸钠,优选每200mg布洛芬中含2mg,及可购得的Tween80(商标);油脂;脂;蜡;及着色剂和香味剂。
优选的其它活性成分选自胶体二氧化硅、玉米淀粉、羟基丙基甲基纤维素、微晶纤维素、聚乙烯吡咯烷酮、乳糖、山梨醇、甘露糖醇、聚乙二醇、油脂、脂、蜡、及着色剂和香味剂。
其它活性组分也可存在,如咖啡咽或其它适用于结合布洛芬和可待因使用的活性物质,例如减充血剂、抗组胺药和止咳素,如假麻黄碱、苯海拉明及类似物质。
从前述可以理解,尽管有许多配方可采用,但固体剂量形式是优选的,并且最优选单相片剂。该片剂优选地包括根据本发明的片剂芯及其上的涂层,该涂层优选含有成膜聚合物的膜,如羟基丙基甲基纤维素;增塑剂如聚乙二醇类(如PEG 400),及可任意选择使用的着色分散剂。优选通过使用有色涂膜为片剂提供颜色,这比加压前将着色剂直接掺入芯颗粒更可取。优选地,涂膜占配方的1%(重量),如需要,片剂可使用标准食品级染料。另外可以为压制而成。
布洛芬和可待因可以,例如前面提及的药物可接受的盐的形式,以任意的治疗有效量存在。例如布洛芬50-2400mg范围,如300-1200mg,优选200-800mg。特别优选的单位剂量配方包含200mg、300mg或600mg的布洛芬,尤其是200mg。可待因10-300mg范围,优选10-100mg;例如,作为半水合磷酸盐,含12-22.5mg,如约13.5mg。
尤其优选的配方中,包含在约660mg,如663mg的片剂芯中含有布洛芬200mg加约13.57mg半水合磷酸可待因(相当于10mg可待因)。任选地,咖啡因含量至多达65mg,优选约30mg。
优选地,配方提供了使最大人用方案剂量为2单位剂量,每日为四次。
这里给出的成分的剂量及组分的重量都遵从通常的药理学的允许剂量,此允许剂量偏差通常为±5%。例如优选的布洛芬成可待因的剂量是标明数值的95%-105%。
本发明的配方可以使用本领域公知的任何方法制备,例如单相片剂可以用直接压缩方法制备,其中片剂芯的所有成分被过筛、混合,然后压制。直接压缩方法避免了预处理粉状成分的需要,如通过湿成粒后干燥。优选地,最后压缩成胶囊形状片剂或“小胶囊(caplets)”。
在更广义上,本发明因此提供了制备配方的一种方法,根据本发明它包括将布洛芬和可待因(或其任一者的盐)与氢化植物油进行组合。优选地,在成分中,以及处理过程中,水分含量保持最少;更优选地,水分含量少于配方的约5%(重量比)。
片剂一旦制成,例如根据本发明的“小胶囊(caplets)”就包装在合适的容器中,例如玻璃或塑料瓶,或者优选地,一种所谓“泡”(blister)包装,如一种包括用铝箔热封的聚氯乙烯“泡”。尤其提供一种所谓“患者包装”,即容器装在一个纸盒里,纸盒内再装有给示配方储存和使用的信息的患者说明页。
本领域技术人员应将理解,本发明进一步提供了根据本发明的配方在治疗中的用途,尤其是治疗或预防前述的任一疾病,特别是缓解中等或严重疼痛。本发明因此提供了治疗疾病的一种方法,这种方法包括给药需治疗的患者有效剂量的根据本发明的药物配方。本发明还进一步提供了布洛芬和可待因在制备根据本发明的药剂上的用途。
现在将在以下列实施例说明本发明,尽管有效实施本发明的其它方法对所属领域技术人员是显见的。实施例1-片剂
片剂芯 mg/片
布洛芬 200.00
半水合磷酸可待因 13.57
氢化植物油 5.00
Cellactose 足量至660mg
Aerosil 3.00
崩解剂* 55.00
*淀粉甘醇酸钠和/或交联羧甲基纤维素钠(Acidi-sol)。
使用直接压缩方法将这些成分一起过筛、混合和压制。
实施例2-片剂
片剂芯 mg/片
布洛芬 200.00
半水合磷酸可待因 13.57
Cellactose 200.00
微晶纤维素 183.43
氢化植物油 5.00
Aerosil 3.00该片剂根据实施例1的方法制备。
实施例3-涂膜片剂
片剂芯 mg/片
布洛芬 200.00
半水合磷酸可待因 13.57
微晶纤维素 182.93
氢化植物油 5.00
淀粉甘醇酸钠 55.00
Aerosil(胶体二氧化硅) 0.50
Cellactose 200.00
该片芯以实施例1的方法制备,然后用下列包含羟基丙基甲基纤维素,PEG 400及适当的颜色分散剂的涂膜剂涂膜。
涂膜剂A
羟基丙基甲基纤维素 6.2846
聚乙二醇400 1.2569
颜色分散剂(1) 2.4584=7.3319mg
(湿时)
涂膜剂B
羟基丙基甲基纤维素 6.0964
聚乙二醇400 1.2193
颜色分散剂(2) 2.6843=7.1126mg
(湿时)
实施例4-涂膜片剂
片剂芯 mg/片
布洛芬 200.00
半水合磷酸可待因 13.57
微晶纤维素 162.93
氢化植物油 5.00
淀粉甘醇酸钠 55.00
Aerosil 0.50
交联羧甲基纤维素钠 20.00
Cellactose 200.00
该片芯以实施例1的方法制备,然后用下列包含羟基丙基甲基纤维素,PEG 400及适当的颜色分散剂的涂膜剂涂膜。
涂膜剂A
羟基丙基甲基纤维素 6.2846
聚乙二醇400 1.2569
颜色分散剂(1) 2.4584=7.3319mg
(湿时)
涂膜剂B
羟基丙基甲基纤维素 6.0964
聚乙二醇400 1.2193
颜色分散剂(2) 2.6843=7.1126mg
(湿时)
实施例5-涂膜片剂
片剂芯 mg/片
布洛芬 200.00
半水合磷酸可待因 13.57
氢化植物油 5.00
淀粉甘醇酸钠 55.00
Aerosil 0.50
交联羧甲基纤维素钠 20.00
Cellactose 362.93
该片剂根据实施例1的方法制备,而后用实施例涂膜剂4A和4B涂膜。
实施例6-含咖啡因片剂
片剂芯 mg/片
布洛芬 200.00
半水合磷酸可待因 13.57
Cellactose 355.08
Sterotex K 5.00
淀粉甘醇酸钠 55.00
咖啡因 30.00
该片剂芯是根据实施例1的方法制备的。可采用根据实施例4A和4B的涂膜方法涂膜本片剂。
实施例7-患者包装
根据实施例3-6制备的涂膜片剂包装在白色、不透光、200微米的聚氯乙烯泡内,并以20微米的铝箔热封。此含泡包装放入有患新信息说明页的硬纸盒中。
Claims (22)
1、一种药剂配方,包含布洛芬或其药学可接受的盐和可待因或其药学可接受的盐结合药学可接受的载体,其中所述的载体含润滑剂、崩解剂和稀释剂,其特征在于:所述的润滑剂基本上不含硬脂酸和硬脂酸盐离子,并选自氢化植物油。
2、根据权利要求1的配方,其中氢化植物油选自氢化豆油和氢化蓖麻油及它们的混合物。
3、根据权利要求1的配方,其中氢化植物油选自甘油酯及其混合物。
4、根据权利要求1的配方,其中氢化植物油是选自C16-C20甘油酯和三(12-羟基)硬脂酸甘油酯。
5、根据权利要求1的配方,其中氢化植物油选自以如下商标出售的氢化植物油中:Sterotex K,Castorwax,Castorwax MP70,Castorwax MP80,Cenwachs G,Cerit CH,Opalwax,Ceroxin及Cutina。
6、根据权利要求1的配方,其中崩解剂选自交联的羧甲基纤维素盐、淀粉甘醇酸盐、聚乙烯吡咯烷酮及它们的混合物。
7、根据权利要求1的配方,其中崩解剂选自交联的聚乙烯吡咯烷酮,交联羧甲基纤维素钠和淀粉甘醇酸钠及它们的混合物。
8、根据权利要求1的配方,其中崩解剂是或包括淀粉甘醇酸钠。
9、根据权利要求1的配方,其中稀释剂选自乳糖和纤维素及它们的混合物。
10、根据权利要求1的配方,其中稀释剂选自Cellactose;微晶纤维素和羧甲基纤维素及它们的混合物。
11、根据权利要求1的配方,其中稀释剂包含乳糖和纤维素及任选的水的混合物。
12、根据权利要求1的配方,其中稀释剂包含重量比基本为3∶1的乳糖和纤维素,以及任选的按乳糖和纤维素的重量计为3-5%w/w的水。
13、根据权利要求1的配方,其中所述载体进一步包括二氧化硅胶体。
14、根据权利要求1的配方,其中还进一步包括选自咖啡因、减充血剂、抗组胺药和止咳素以及它们的混合物的其它活性成分。
15、根据权利要求1的配方,其中包括50-2400mg的布洛芬和10-300mg的可待因。
16、根据权利要求1的配方,其中包括200mg的布洛芬和13.57mg的半水合磷酸可待因;以及任选的30mg咖啡咽。
17、根据权利要求1的配方,其为片剂形式。
18、根据权利要求1的配方,其特征还在于其如本文中所定义的那样,基本上不含金属离子。
19、制备根据权利要求1的配方的方法,此方法包括将布洛芬和可待因或二者的药学上可接受的盐与氢化植物油组合。
20、根据权利要求19的方法,其中包括将布洛芬和可待因或二者的药学上可接受的盐与药学上可接受的载体组合,所述的载体包含:
a)、C16-C20甘油脂和/或三(12-羟基)硬脂酸甘油酯;
b)、交联的羧甲基纤维素盐和/或淀粉甘醇酸盐;和
c)、乳糖和纤维素及任选的水的混合物。
21、根据权利要求19的方法,其中所述的载体进一步包括二氧化硅,和/或将选自咖啡因、减充血剂、抗组胺药和止咳素以及它们的混合物的其它活性成分也与所述的载体组合。
22、根据权利要求19的方法,其中所有成分一起过筛、混合,然后压制。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9417041A GB9417041D0 (en) | 1994-08-23 | 1994-08-23 | Improved formulations |
GB9419921A GB9419921D0 (en) | 1994-10-04 | 1994-10-04 | Improved formulations |
GB9419921.3 | 1994-10-04 | ||
GB9417041.2 | 1994-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1159754A CN1159754A (zh) | 1997-09-17 |
CN1083265C true CN1083265C (zh) | 2002-04-24 |
Family
ID=26305507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95195426A Expired - Fee Related CN1083265C (zh) | 1994-08-23 | 1995-08-16 | 改进的含有布洛芬和可待因的药物配方 |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP0777477B1 (zh) |
JP (1) | JP3874793B2 (zh) |
KR (1) | KR100397082B1 (zh) |
CN (1) | CN1083265C (zh) |
AT (1) | ATE227574T1 (zh) |
AU (1) | AU699224B2 (zh) |
BG (1) | BG63329B1 (zh) |
BR (1) | BR9508760A (zh) |
CA (1) | CA2156768A1 (zh) |
CZ (1) | CZ287558B6 (zh) |
DE (1) | DE69528838T2 (zh) |
DK (1) | DK0777477T3 (zh) |
ES (1) | ES2187566T3 (zh) |
HU (1) | HU227759B1 (zh) |
MX (1) | MX9701390A (zh) |
NO (1) | NO322200B1 (zh) |
NZ (1) | NZ291223A (zh) |
PL (1) | PL181215B1 (zh) |
PT (1) | PT777477E (zh) |
RU (1) | RU2140782C1 (zh) |
SK (1) | SK282183B6 (zh) |
TW (1) | TW493984B (zh) |
UA (1) | UA42781C2 (zh) |
WO (1) | WO1996005834A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608073B1 (en) | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
US6368618B1 (en) | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
JP2001253826A (ja) * | 2000-03-09 | 2001-09-18 | Maruzen Pharmaceut Co Ltd | 内服用剤 |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
ZA200803566B (en) * | 2005-12-12 | 2009-10-28 | Adcock Ingram Ltd | Pharmaceutical compositions |
WO2008000760A1 (en) | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
US8034801B2 (en) | 2006-07-12 | 2011-10-11 | Aska Pharmaceutical Co., Ltd. | Analgesic agent |
BRPI0716439B8 (pt) | 2006-08-14 | 2021-05-25 | Boehringer Ingelheim Int | sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos |
BRPI0716436B8 (pt) | 2006-08-25 | 2021-05-25 | Boehringer Ingelheim Int | sistema de liberação controlada e método para fabricação do mesmo |
WO2008044331A1 (fr) * | 2006-10-05 | 2008-04-17 | Kowa Company, Ltd. | Préparation solide comprenant de l'ibuprofène et de l'acide tranexamique |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
PT2279731E (pt) | 2008-04-23 | 2013-08-30 | Farmasierra Mfg S L | Composição farmacêutica melhorada contendo ibuprofeno e codeína |
ES2365961B1 (es) * | 2010-03-30 | 2013-01-24 | Farmasierra Manufacturing S.L. | Formulación farmacéutica a base de ibuprofeno y codeína de estabilidad mejorada. |
KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
KR20140096571A (ko) | 2013-01-28 | 2014-08-06 | 한미약품 주식회사 | 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법 |
BR112017003430A2 (pt) | 2014-08-28 | 2017-11-28 | Sanofi Aventis De Mexico Sa De Cv | comprimido revestido com filme para o tratamento de dor aguda |
CN105395508B (zh) * | 2015-12-14 | 2018-06-29 | 西南药业股份有限公司 | 一种洛芬待因复方制剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4571400A (en) * | 1984-12-18 | 1986-02-18 | Belleview Pharmaceutical, Inc. | Dihydrocodeine/ibuprofen pharmaceutical compositions and method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8905815D0 (en) * | 1989-03-14 | 1989-04-26 | Beecham Group Plc | Medicament |
GB9121204D0 (en) * | 1991-10-04 | 1991-11-20 | Euro Celtique Sa | Medicament |
-
1995
- 1995-08-16 EP EP95928574A patent/EP0777477B1/en not_active Expired - Lifetime
- 1995-08-16 DK DK95928574T patent/DK0777477T3/da active
- 1995-08-16 AU AU32289/95A patent/AU699224B2/en not_active Ceased
- 1995-08-16 RU RU97104235A patent/RU2140782C1/ru active
- 1995-08-16 DE DE69528838T patent/DE69528838T2/de not_active Expired - Lifetime
- 1995-08-16 ES ES95928574T patent/ES2187566T3/es not_active Expired - Lifetime
- 1995-08-16 PT PT95928574T patent/PT777477E/pt unknown
- 1995-08-16 CN CN95195426A patent/CN1083265C/zh not_active Expired - Fee Related
- 1995-08-16 HU HU9701774A patent/HU227759B1/hu unknown
- 1995-08-16 AT AT95928574T patent/ATE227574T1/de active
- 1995-08-16 NZ NZ291223A patent/NZ291223A/xx not_active IP Right Cessation
- 1995-08-16 JP JP50785696A patent/JP3874793B2/ja not_active Expired - Fee Related
- 1995-08-16 SK SK236-97A patent/SK282183B6/sk not_active IP Right Cessation
- 1995-08-16 PL PL95318807A patent/PL181215B1/pl not_active IP Right Cessation
- 1995-08-16 KR KR1019970701128A patent/KR100397082B1/ko not_active IP Right Cessation
- 1995-08-16 UA UA97020807A patent/UA42781C2/uk unknown
- 1995-08-16 BR BR9508760A patent/BR9508760A/pt not_active IP Right Cessation
- 1995-08-16 CZ CZ1997546A patent/CZ287558B6/cs not_active IP Right Cessation
- 1995-08-16 WO PCT/GB1995/001947 patent/WO1996005834A1/en active IP Right Grant
- 1995-08-22 TW TW084108754A patent/TW493984B/zh not_active IP Right Cessation
- 1995-08-23 CA CA002156768A patent/CA2156768A1/en not_active Abandoned
-
1997
- 1997-02-20 NO NO19970782A patent/NO322200B1/no not_active IP Right Cessation
- 1997-02-21 BG BG101252A patent/BG63329B1/bg unknown
- 1997-02-24 MX MX9701390A patent/MX9701390A/es not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4571400A (en) * | 1984-12-18 | 1986-02-18 | Belleview Pharmaceutical, Inc. | Dihydrocodeine/ibuprofen pharmaceutical compositions and method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1083265C (zh) | 改进的含有布洛芬和可待因的药物配方 | |
CN1160079C (zh) | 发泡性肠溶制剂 | |
JP5465824B2 (ja) | 医薬用製剤およびその製造方法 | |
EP1274402B1 (en) | Pharmaceutical composition for the controlled release of paracetamol | |
JP2009513669A (ja) | 親水性ベヒクルに基づく二重制御された放出マトリクスシステム | |
CN110051642A (zh) | 包含包封于硬胶囊中的多单元球状片剂(must)的复合制剂及其制备方法 | |
RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
JP2009227651A (ja) | 活性成分の調整放出が可能な分割可能なガレヌス形態 | |
CN1253497A (zh) | 含扑热息痛的吞咽片剂 | |
CN101073563A (zh) | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 | |
CN1142766A (zh) | 解热镇痛组合药剂 | |
WO2005046727A2 (en) | Ibuprofen-containing soft gelatin capsules | |
JP2001511168A (ja) | 偏頭痛の治療のためのイブプロフェンおよびドンペリドンを含有する製薬組成物 | |
JPH05246845A (ja) | イブプロフェン含有解熱鎮痛剤 | |
JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
JP2013163698A (ja) | 医薬用製剤およびその製造方法 | |
JP5593420B2 (ja) | イブプロフェンの昇華が抑制された固形製剤 | |
JP6106359B2 (ja) | ロキソプロフェンナトリウムとビタミンb1を含有する固形製剤 | |
JPH0797325A (ja) | 安定な固形製剤およびその製造法 | |
CN1309557A (zh) | 含有帕罗西汀的新制剂 | |
JP4899304B2 (ja) | 塩酸アンブロキソール含有内服用固形製剤 | |
US11707466B2 (en) | Immediate release multilayer tablet | |
CN1415613A (zh) | 地洛他定盐及含有该盐的用于治疗过敏性疾病的稳定的药物组合物 | |
JP6197513B2 (ja) | 医薬組成物 | |
JP2021102609A (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20020424 Termination date: 20130816 |